ES2566973T3 - Uso de SNS-595 para tratar leucemia - Google Patents

Uso de SNS-595 para tratar leucemia Download PDF

Info

Publication number
ES2566973T3
ES2566973T3 ES10177951.0T ES10177951T ES2566973T3 ES 2566973 T3 ES2566973 T3 ES 2566973T3 ES 10177951 T ES10177951 T ES 10177951T ES 2566973 T3 ES2566973 T3 ES 2566973T3
Authority
ES
Spain
Prior art keywords
sns
treat leukemia
obs
patient
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10177951.0T
Other languages
English (en)
Spanish (es)
Other versions
ES2566973T9 (es
Inventor
Daniel C. Adelman
Jeffrey A. Silverman
Higaki Masaru
Nakao Satoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Viracta Therapeutics Inc
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sunesis Pharmaceuticals Inc filed Critical Sumitomo Dainippon Pharma Co Ltd
Application granted granted Critical
Publication of ES2566973T3 publication Critical patent/ES2566973T3/es
Publication of ES2566973T9 publication Critical patent/ES2566973T9/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S10/00—Solar heat collectors using working fluids
    • F24S10/70—Solar heat collectors using working fluids the working fluids being conveyed through tubular absorbing conduits
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S50/00—Arrangements for controlling solar heat collectors
    • F24S50/40—Arrangements for controlling solar heat collectors responsive to temperature
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S80/00—Details, accessories or component parts of solar heat collectors not provided for in groups F24S10/00-F24S70/00
    • F24S80/60—Thermal insulation
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S40/00—Components or accessories in combination with PV modules, not provided for in groups H02S10/00 - H02S30/00
    • H02S40/30—Electrical components
    • H02S40/38—Energy storage means, e.g. batteries, structurally associated with PV modules
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S40/00—Components or accessories in combination with PV modules, not provided for in groups H02S10/00 - H02S30/00
    • H02S40/40—Thermal components
    • H02S40/44—Means to utilise heat energy, e.g. hybrid systems producing warm water and electricity at the same time
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F77/00—Constructional details of devices covered by this subclass
    • H10F77/40—Optical elements or arrangements
    • H10F77/42—Optical elements or arrangements directly associated or integrated with photovoltaic cells, e.g. light-reflecting means or light-concentrating means
    • H10F77/488—Reflecting light-concentrating means, e.g. parabolic mirrors or concentrators using total internal reflection
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F77/00—Constructional details of devices covered by this subclass
    • H10F77/60—Arrangements for cooling, heating, ventilating or compensating for temperature fluctuations
    • H10F77/63—Arrangements for cooling directly associated or integrated with photovoltaic cells, e.g. heat sinks directly associated with the photovoltaic cells or integrated Peltier elements for active cooling
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/40—Solar thermal energy, e.g. solar towers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/40—Solar thermal energy, e.g. solar towers
    • Y02E10/44—Heat exchange systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/52—PV systems with concentrators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/60—Thermal-PV hybrids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E70/00—Other energy conversion or management systems reducing GHG emissions
    • Y02E70/30—Systems combining energy storage with energy generation of non-fossil origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Combustion & Propulsion (AREA)
  • Thermal Sciences (AREA)
  • Sustainable Energy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
ES10177951.0T 2004-03-15 2005-03-14 Uso de SNS-595 para tratar leucemia Expired - Lifetime ES2566973T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55357804P 2004-03-15 2004-03-15
US553578P 2004-03-15

Publications (2)

Publication Number Publication Date
ES2566973T3 true ES2566973T3 (es) 2016-04-18
ES2566973T9 ES2566973T9 (es) 2017-01-03

Family

ID=34993432

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10177951.0T Expired - Lifetime ES2566973T3 (es) 2004-03-15 2005-03-14 Uso de SNS-595 para tratar leucemia
ES05732554T Expired - Lifetime ES2334802T3 (es) 2004-03-15 2005-03-14 Sns-595 y metodos de uso del mismo.
ES05731600T Expired - Lifetime ES2358267T3 (es) 2004-03-15 2005-03-14 Composición farmacéutica que comprende sns-595 y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES05732554T Expired - Lifetime ES2334802T3 (es) 2004-03-15 2005-03-14 Sns-595 y metodos de uso del mismo.
ES05731600T Expired - Lifetime ES2358267T3 (es) 2004-03-15 2005-03-14 Composición farmacéutica que comprende sns-595 y sus usos.

Country Status (23)

Country Link
US (12) US7989468B2 (enExample)
EP (4) EP3053579A1 (enExample)
JP (9) JP5096913B2 (enExample)
KR (1) KR101169825B1 (enExample)
CN (5) CN104324029A (enExample)
AT (2) ATE493982T1 (enExample)
AU (3) AU2005222622B2 (enExample)
BR (1) BRPI0508700A (enExample)
CA (3) CA2954578A1 (enExample)
CY (2) CY1109741T1 (enExample)
DE (2) DE602005018333D1 (enExample)
DK (3) DK1729770T3 (enExample)
ES (3) ES2566973T3 (enExample)
HU (1) HUE027266T2 (enExample)
IL (2) IL177946A (enExample)
MX (2) MX349188B (enExample)
NO (3) NO338058B1 (enExample)
NZ (2) NZ549557A (enExample)
PL (3) PL1729770T3 (enExample)
PT (2) PT1729770E (enExample)
SI (2) SI1725233T1 (enExample)
WO (2) WO2005089757A1 (enExample)
ZA (1) ZA200607248B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566973T3 (es) 2004-03-15 2016-04-18 Sunesis Pharmaceuticals, Inc. Uso de SNS-595 para tratar leucemia
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
MX2007003282A (es) 2004-09-17 2007-10-16 Cylene Pharmaceuticals Inc Analogos de quinolona.
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2620915C (en) * 2005-09-02 2014-03-25 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP2043645A2 (en) 2006-06-12 2009-04-08 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2049109B1 (en) * 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
AU2014277779B2 (en) * 2007-10-22 2016-05-19 Sunesis Pharmaceuticals, Inc. METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
EP3141250A1 (en) * 2007-10-22 2017-03-15 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US20110008371A1 (en) * 2007-12-10 2011-01-13 Sunesis Pharmaceuticals, Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
CN102341393B (zh) * 2008-12-31 2014-09-17 逊尼希思制药公司 制备(+)-1，4-二氢-7-[(3s，4s)-3-甲氧基-4-甲氨基-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1，8-萘啶-3-羧酸的方法
CN102405045A (zh) * 2009-02-27 2012-04-04 逊尼希思制药公司 利用sns-595 治疗具有降低的brca2 活性的癌症对象的方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2819498B1 (en) 2012-02-27 2017-02-15 AGQ Technological Corporate S.A. Monitoring and control of soil conditions
RS58043B1 (sr) 2012-04-24 2019-02-28 Vertex Pharma Inhibitori dna-pk
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
US20160136173A1 (en) * 2013-07-02 2016-05-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III
PE20161022A1 (es) 2013-10-17 2016-11-12 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CA3038657A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
WO2025033367A1 (ja) * 2023-08-04 2025-02-13 湧永製薬株式会社 抗腫瘍剤併用療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216316A (en) * 1879-06-10 Improvement in latches
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE69524251T2 (de) * 1994-06-14 2002-07-11 Dainippon Pharmaceutical Co., Ltd. Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
DK0966683T3 (da) * 1997-01-13 2003-08-04 Kudos Pharm Ltd Assays, midler, terapi og diagnose vedrørende moduleirng af cellulær DNA-reparationsaktivitet
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
WO1998055615A1 (en) 1997-06-05 1998-12-10 The University Of Texas Board Or Regents Apaf-1, the ced-4 human homolog, an activator of caspase-3
US6171857B1 (en) 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
DE69936141T2 (de) * 1998-06-30 2008-01-31 Sloan-Kettering Institute For Cancer Research Verwendung von dna-pk
CA2363621A1 (en) 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) * 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
CA2408749A1 (en) * 2000-05-20 2001-11-29 Cancer Research Technology Limited Drug screening systems and assays
AU2001288432A1 (en) * 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
EP1337275A4 (en) * 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
AU2003253593A1 (en) * 2002-04-05 2003-11-03 Richard A. Fishel Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
ES2566973T3 (es) * 2004-03-15 2016-04-18 Sunesis Pharmaceuticals, Inc. Uso de SNS-595 para tratar leucemia
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP2043645A2 (en) 2006-06-12 2009-04-08 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
WO2008016678A2 (en) 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2049109B1 (en) 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
EP3141250A1 (en) 2007-10-22 2017-03-15 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US20110008371A1 (en) 2007-12-10 2011-01-13 Sunesis Pharmaceuticals, Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
CN102341393B (zh) 2008-12-31 2014-09-17 逊尼希思制药公司 制备(+)-1，4-二氢-7-[(3s，4s)-3-甲氧基-4-甲氨基-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1，8-萘啶-3-羧酸的方法
CN102405045A (zh) 2009-02-27 2012-04-04 逊尼希思制药公司 利用sns-595 治疗具有降低的brca2 活性的癌症对象的方法
CN101631081B (zh) 2009-08-12 2011-06-08 华为技术有限公司 一种多级交换网
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
NO20161867A1 (no) 2006-10-12
ES2566973T9 (es) 2017-01-03
US20130244967A1 (en) 2013-09-19
AU2005222622B2 (en) 2011-04-07
US20110263524A1 (en) 2011-10-27
DK1729770T3 (da) 2010-04-12
US20180316309A1 (en) 2018-11-01
EP2295056B9 (en) 2016-09-28
US9980949B2 (en) 2018-05-29
NZ549557A (en) 2010-10-29
JP5317472B2 (ja) 2013-10-16
US20170373636A9 (en) 2017-12-28
AU2011201277A1 (en) 2011-04-07
JP6261477B2 (ja) 2018-01-17
DK2295056T5 (en) 2016-11-28
US20150190381A1 (en) 2015-07-09
US7989468B2 (en) 2011-08-02
EP1725233B1 (en) 2011-01-05
US20050215583A1 (en) 2005-09-29
CN1997368B (zh) 2014-10-22
JP5096913B2 (ja) 2012-12-12
SI1729770T1 (sl) 2010-02-26
JP6352863B2 (ja) 2018-07-04
US20060247267A1 (en) 2006-11-02
JP2015017110A (ja) 2015-01-29
CA2559650A1 (en) 2005-09-29
KR20070033966A (ko) 2007-03-27
NO339613B1 (no) 2017-01-16
EP2295056B1 (en) 2016-01-06
JP2007529524A (ja) 2007-10-25
CN103251589A (zh) 2013-08-21
CA2559650C (en) 2013-11-19
NO338058B1 (no) 2016-07-25
US20060025437A1 (en) 2006-02-02
PL1729770T3 (pl) 2010-05-31
CA2559652A1 (en) 2005-09-29
PL2295056T3 (pl) 2016-07-29
ES2334802T3 (es) 2010-03-16
US20050203120A1 (en) 2005-09-15
EP1729770B1 (en) 2009-12-16
MX349188B (es) 2017-07-17
US20060063795A1 (en) 2006-03-23
MXPA06010382A (es) 2007-04-23
CA2954578A1 (en) 2005-09-29
CN101703508A (zh) 2010-05-12
WO2005089757A1 (en) 2005-09-29
CN1997368A (zh) 2007-07-11
CA2559652C (en) 2017-02-14
JP2007529528A (ja) 2007-10-25
BRPI0508700A (pt) 2007-08-07
EP3053579A1 (en) 2016-08-10
CN103083316A (zh) 2013-05-08
DK1725233T3 (da) 2011-03-14
US20110312988A1 (en) 2011-12-22
IL248049A0 (en) 2016-11-30
NO20150466L (no) 2006-10-12
HK1097196A1 (en) 2007-06-22
ZA200607248B (en) 2009-02-25
JP2015227351A (ja) 2015-12-17
EP2295056A1 (en) 2011-03-16
JP5856644B2 (ja) 2016-02-10
US8822493B2 (en) 2014-09-02
US20160361302A1 (en) 2016-12-15
NZ588060A (en) 2011-09-30
SI1725233T1 (sl) 2011-04-29
AU2005222607A1 (en) 2005-09-29
AU2011201277B2 (en) 2012-11-29
US7968565B2 (en) 2011-06-28
PT1725233E (pt) 2011-03-23
JP2012140442A (ja) 2012-07-26
AU2005222607B2 (en) 2010-11-25
DK2295056T3 (en) 2016-04-11
ATE451924T1 (de) 2010-01-15
AU2005222622A1 (en) 2005-09-29
KR101169825B1 (ko) 2012-07-30
JP2018119977A (ja) 2018-08-02
PT1729770E (pt) 2010-02-08
ES2358267T3 (es) 2011-05-09
HUE027266T2 (en) 2016-10-28
IL177946A (en) 2016-10-31
EP1725233A4 (en) 2009-05-20
CN103083316B (zh) 2015-09-30
WO2005089756A1 (en) 2005-09-29
US9757363B2 (en) 2017-09-12
US20140378505A1 (en) 2014-12-25
EP1725233A1 (en) 2006-11-29
JP2011225590A (ja) 2011-11-10
CY1111263T1 (el) 2015-08-05
NO20064647L (no) 2006-10-12
PL1725233T3 (pl) 2011-05-31
JP2014148535A (ja) 2014-08-21
CN104324029A (zh) 2015-02-04
EP1729770A1 (en) 2006-12-13
JP2017095471A (ja) 2017-06-01
CN103251589B (zh) 2015-09-30
EP1729770A4 (en) 2007-04-11
IL177946A0 (en) 2007-03-08
US7829577B2 (en) 2010-11-09
DE602005018333D1 (de) 2010-01-28
US8669270B2 (en) 2014-03-11
ATE493982T1 (de) 2011-01-15
CY1109741T1 (el) 2014-09-10
DE602005025738D1 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
ES2566973T3 (es) Uso de SNS-595 para tratar leucemia
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
CY1111159T1 (el) Πυκνα διαλυματα μεθοτρεξατης
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
BR112020014160A2 (pt) Compostos de benzamida
AR034283A1 (es) Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
RU2013121788A (ru) Ингибиторы репликации вич
UY28578A1 (es) Derivados de amida
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
RU2004133347A (ru) Лекарственное средство для профилактики и/или лечения хронического отторжения
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
ATE430564T1 (de) Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
JP2018530578A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
JPH0543711B2 (enExample)
US20190029996A1 (en) composition containing artesunate
BRPI0409380A (pt) composições farmacêuticas
SE0002476D0 (sv) New compounds
ES2323137T3 (es) Composicion antiparasitaria que contiene una sal de amina organica de closantel.
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.